<unk>  is a human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor that is FDA approved for the treatment of HIV-1 Infection, pre-exposure prophylaxis to HIV-1. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include rash, lactic acidosis, abdominal pain, diarrhea, nausea, serum amylase raised, backache, myalgia, osteopenia, dizziness, headache, insomnia, peripheral neuropathy, depression, dream disorder, pneumonia, fatigue.
Emtricitabine and tenofovir disoproxil fumarate
Emtricitabine and tenofovir alafenamide fumarate
Emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide fumarate
Efavirenz, emtricitabine and tenofovir disoproxil fumarate
Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide
Efavirenz, Emtricitabine, and Tenofovir disoproxil fumarate
Dolutegravir / rilpivirine
Bictegravir / emtricitabine / tenofovir alafenamide